Gerling V, Lahpor J R, Buhre W
Department of Cardiothoracic Anaesthesia, University Medical Center, Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. V.Gerlingumcutrecht.nl
Anaesthesia. 2007 Apr;62(4):405-8. doi: 10.1111/j.1365-2044.2007.05001.x.
We describe a patient with type 2N von Willebrand's disease scheduled for elective coronary artery bypass graft for severe three-vessel coronary artery disease with involvement of the left main stem. He was given a pre-operative bolus of 3000 IU factor VIII/Willebrand factor concentrate (approximately 40 IU.kg(-1)), followed by a continuous infusion of 3 IU.h(-1) (228 IU.h(-1)) before undergoing coronary surgery with full heparinisation and cardiopulmonary bypass. There were no intra-operative bleeding complications and only one unit of packed red blood cells was required postoperatively. Thromboprophylaxis with low-molecular weight heparin and aspirin was given and the infusion of factor VIII/von Willebrand factor concentrate continued for 2 days. As a result of haematological monitoring, heparin therapy was changed from prophylactic to therapeutic on day 5-6 and stopped on day 7.
我们描述了一名患有2N型血管性血友病的患者,计划接受择期冠状动脉搭桥手术,以治疗严重的三支血管冠状动脉疾病,累及左主干。术前给予3000 IU的VIII因子/血管性血友病因子浓缩物推注(约40 IU·kg⁻¹),随后在进行充分肝素化和体外循环的冠状动脉手术前,持续输注3 IU·h⁻¹(228 IU·h⁻¹)。术中无出血并发症,术后仅需输注一个单位的浓缩红细胞。给予低分子量肝素和阿司匹林进行血栓预防,VIII因子/血管性血友病因子浓缩物的输注持续2天。由于血液学监测,肝素治疗在第5 - 6天从预防性改为治疗性,并在第7天停止。